PUBLIC COMPANY
saveTranscend Therapeutics Inc
updated 15d ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)
- phase2A Study to Assess the Use of Methylone in the Treatment of PTSD
- phase2An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD
- phase2An Evaluation of the Long-term Efficacy and Safety of Methylone for the Treatment of PTSD
- phase1A Single, Ascending Dose Evaluation of the Safety, Pharmacokinetics of Methylone in Healthy Subjects
🐶 Hiring Signal
News
- Psychedelics on the cusp of market breakthrough as clinical, policy support growWhile there are several FDA-approved psychiatric medicines on the market, many patients still struggle to achieve lasting symptom relief. Psychedelics could help fill this gap.biospace · 4d ago
- Lilly’s $3.8B psychedelics bet won’t open the M&A floodgatesEli Lilly’s $3.8 billion play for AtaiBeckley has fueled speculation that Big Pharma is ready to embrace psychedelics. But while the acquisition does validate the drug class, analysts say it is unl…biospace · 21d ago
- Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelicsEli Lilly’s proposed acquisition of AtaiBeckley is “the clearest strategic validation to date” of psychedelics as an emerging pharmaceutical category, according to H.C. Wainwright. The analyst caut…biospace · 25d ago
- ‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelicsAfter Eli Lilly dived into the psychedelics space with a $2.8 billion upfront acquisition of AtaiBeckley last week, industry experts told Fierce that the deal would give the space added momentum.fiercebiotech · 27d ago
- Lilly to buy AtaiBeckley for $2.8B, further validating psychedelicsThe latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally be embracing a long-dismissed field of research.biopharma_dive · 29d ago
- STAT+: FDA to speed up review of three psychedelics as mental health treatmentsTrump's embrace of psychedelics and cannabis is shaking up the GOP’s relationship with mind-altering substances.stat · 3mo ago
comments(0)
5-min edit window · permanent after that